Zealand Pharma oplever eksplosiv vækst på børsen efter positive resultater med vægttabsmedicin! 💊💰 #ZealandPharma #Vægttab #Børsen
Zealand Pharma, et dansk biotekselskab, har for nylig oplevet en markant stigning i deres aktiekurs på børsen. Den seneste udvikling kommer efter virksomhedens positive resultater med en ny vægttabsmedicin, som kunne revolutionere markedet. Zealand Pharma blev belønnet med en stigning på mere end 23% efter offentliggørelsen af lovende resultater fra kliniske forsøg, der viser en gennemsnitlig vægtreduktion på imponerende 8.6% over en 16-ugers periode.
Virksomheden præsenterede petrelintide som en potentiel game-changer inden for vægtstyring og hævdede, at den kan være rygraden i behandlingen på grund af dens effektivitet, der minder om GLP-1 uden de tilhørende bivirkninger. Dette har skabt stor spænding i branchen, da markedet ser frem til et alternativ til eksisterende vægttabsmedicin som Ozempic og Wegovy.
Det imponerende spring i aktiekursen tiltrak investorer, og Zealand Pharma blev genstand for stor opmærksomhed på børsen. Virksomhedens ambition om at levere en bedre patientoplevelse med deres nye vægttabsmedicin har sat dem på kortet som en vigtig spiller i biotekindustrien.
Zealand Pharma's positive resultater med petrelintide har positioneret dem som en markant konkurrent til eksisterende vægttabsmedicin på markedet. Deres fokus på patientoplevelsen og effektiviteten af produktet har skabt stor forventning i branchen, og investorer følger nøje med i virksomhedens videre udvikling.
European stocks were weaker at the open on Friday as investors digested data from the UK that showed a rise in retail sales last month, but also government ...
The Danish company is testing a rival to drugs such as Ozempic and Wegovy which it says may deliver a “better patient experience.”
By Barbara Kollmeyer. Shares of Zealand Pharma soared on Friday after the Danish biotech company reported positive results from a trial of its experimental ...
Patients in the study showed an average weight loss of 8.6 percent with a high weekly dose of petrelintide over a 16-week period.
... ** Shares in Zealand Pharma ZELA.CO jump more than 23%, touching a record high of DKK 824.50, after the Danish drugmaker posted positive topline data ...
Zealand said petrelintide can be “the backbone of therapy for weight management” because it may provide GLP-1-like efficacy without the side effects.
Shares of Zealand Pharma soared on Friday after the Danish biotech company reported positive results from a trial of its experimental weight-loss injection, ...
US stock futures drift lower; Nvidia loses most valuable titl.
Zealand Pharma's share price soared on the Copenhagen Stock Exchange on Friday, following the biotech company's announcement of positive results from a ...
Zealand Pharma believes its weight loss drug petrelintide could be comparable to glucagon like peptide-1 receptor agonists (GLP1-RAs) while providing a ...
The Danish pharmaceutical firm said its new weight loss drug could compare to Ozempic, Wegovy and other GLP-1 drugs.
Zealand Pharma said late Thursday that a course of 16 weekly high doses of long-acting amylin analog petrelintide reduced body weight by up to 8.6% on ...
Shares of Denmark's Zealand Pharma (ZEAL.CO) are surging after an early-stage study of its weight-loss drug produced positive results.
The Danish company is testing a rival to drugs such as Ozempic and Wegovy that it says may deliver a "better patient experience."
Zealand Pharma surged 23% after it announced positive clinical trial results for its experimental weight loss drug petrelintide.
Read Reviewing Taylor Wimpey (OTCMKTS:TWODY) and Zealand Pharma A/S (OTCMKTS:ZLDPF) at Defense World.